Ann: Opthea Completes COAST Final Week 52 Patient Visit, page-8

Agreed, which is odd as I’d suggest that OPT has an unusually high probability of success. The existing strong data, the unusually strong management team backing this drug (as I explained last night), the FDA fast track designation (they also back this based on what they’ve seen and want it to market ASAP), and of course, the observation from the P3 trial that average BCVA is higher than what would be expected with the control alone all provides substantial reassurance that we are indeed sitting on the real deal here. Based on expected earnings, the share price rise has really only just begun. The real fun starts now, as we move towards $10 and beyond (a more fitting valuation for a company with such a large addressable market, and such a disruptive and sought after product)